Philips today announced the sale of its technology platform for rapid fully-automated DNA/RNA molecular diagnostic testing to Swiss company Biocartis. The technology, the product of a broad R&D personalised medicine programme that Philips started in early 2000, does not fit its ...
Please Login to read the full article.
